The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy.
Carlo Gambacorti-Passerini
Consultant or Advisory Role - Bristol-Myers Squibb; Pfizer
Honoraria - Nadirex; Pfizer
Research Funding - Pfizer
Tim H. Brummendorf
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; ChemGenex; Novartis; Pfizer
Jeffrey H. Lipton
No relevant relationships to disclose
Dong-Wook Kim
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Eric Leip
Employment or Leadership Position - Pfizer
Kathleen Wyant Turnbull
Employment or Leadership Position - Pfizer
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer